FORT MILL, S.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the recent addition of key ablation procedures to ambulatory surgery centers (ASC) by Centers for Medicare and Medicaid services (CMS) provides a unique and new opportunity to expand the commercialization of LockeT. In a recent announcement by Heart Rhythm Ad ...

FORT MILL, S.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announces the rapid commercial uptake of its LockeT closure device in South Africa. With the assistance of local distributor, HLC Medical and Dr. Heather Henry-Lines, LockeT was successfully implemented in five hospitals within two months. Three of these hospitals are using ...

First-ever multi-year agreement highlights commitment to French electrophysiology marketFORT MILL, S.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announces its third VIVO™ system installation in France, at the prestigious Centre Hospitalier Régional Universitaire (CHRU) Nancy. Led by Prof. Christian de Chillou, a renowned expert in ...

Financial Results Announcement - Catheter Precision, Inc. announced its financial results for the three and nine months ended September 30, 2025[4]. - The press release detailing the financial results was issued on November 13, 2025[4]. - The financial results include key metrics that will be detailed in Exhibit 99.1 attached to the report[5]. Company Information - The company is listed on the NYSE American under the trading symbol VTAK[2]. - The company is based in Fort Mill, SC, with a principal executive office address provided[1]. Regulatory Compliance - The report indicates that Catheter Precision, Inc. is not an emerging growth company[3]. - The report does not incorporate any information as "filed" under the Securities Exchange Act of 1934[5]. - The report is part of the requirements set forth by the Securities Exchange Act of 1934[8]. Report Details - The Chief Financial Officer, Philip Anderson, signed the report on November 14, 2025[10]. - The report includes an interactive data file formatted as inline XBRL[6].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-38677 Catheter Precision, Inc. (Exact name of registrant as specified in its charter) Delaware 38-3661826 (State or other jurisdiction of incorporation or ...

Sales Revenue Up 135% over Q3 2024FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial Highlights Total revenue reported for Q3 2025 was $226,000, an increase of 135% compared with $96,000 in Q3 2024.Total ...

Core Insights - Catheter Precision, Inc. has entered into a strategic distribution agreement with FuMedica AG to introduce its LockeT suture retention device in Switzerland [1][4] - The LockeT device is designed to simplify and secure the closure of vascular access sites after cardiac procedures, enhancing procedural outcomes [2][5] - FuMedica AG is recognized for its excellence in distributing advanced medical technologies, particularly in cardiology, making it a suitable partner for Catheter Precision [3][7] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias and electrophysiology procedures [6] - The company aims to improve treatment outcomes through collaboration with physicians and continuous product advancement [6] Product Details - The LockeT device is classified as a Class 1 medical device registered with the FDA and has received CE Mark approval, indicating its compliance with European health standards [5] - Its intuitive design and reliable performance have made it a valuable tool in electrophysiology labs and interventional suites globally [2] Partnership Significance - The agreement with FuMedica AG is a key milestone in Catheter Precision's European growth strategy, leveraging FuMedica's market knowledge and commitment to quality [4] - The partnership reflects Catheter Precision's dedication to global collaboration and innovation in cardiac care [4]

Core Insights - Catheter Precision, Inc. has received notification from the United States Patent and Trademark Office regarding the allowance for two new patents, enhancing its intellectual property portfolio in the cardiac electrophysiology market [1][4]. Patent Details - The first patent is titled "Methods of Ventricular Arrhythmia Localization Using a 3D Model," which will be assigned to Kardionav, a joint venture aimed at developing new applications for cardiac ventricular therapies [2]. - The second patent, "Neurostimulation Devices and Methods," focuses on improving cardiac ventricular function, particularly for heart failure patients, and will be assigned to Cardionomix, a subsidiary of Catheter Precision [3]. Company Overview - Catheter Precision is a U.S.-based medical device company dedicated to innovating solutions for cardiac arrhythmias, emphasizing collaboration with physicians and continuous product advancement [6]. - The company's VIVO technology is a non-invasive 3D imaging system that helps identify the origins of ventricular arrhythmias before procedures, thereby improving workflow and reducing procedure time [5].

Core Insights - Catheter Precision, Inc. has received its first purchase order from Dubrava Hospital in Croatia after winning a competitive tender bid, marking a significant milestone for the company in expanding its market presence in Europe [1][2][3] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, particularly in the electrophysiology market [4] - The company collaborates with physicians to continuously advance its products and improve patient care [4] Product Details - The VIVO (View Into Ventricular Onset) system is a non-invasive 3D imaging technology that helps physicians identify the origin of ventricular arrhythmias before procedures, thereby enhancing workflow and reducing procedure time [3] - VIVO has received marketing clearance from the U.S. FDA and holds the CE Mark, indicating its compliance with European health standards [3] Hospital Evaluation - Dubrava University Hospital, a leading hospital in Croatia, evaluated the VIVO system before including it in the bidding process, highlighting its simple and flexible workflow and the accuracy of its mapping capabilities [2] - The hospital treats over 25,000 inpatients annually and provides more than 1,500,000 health services to over 400,000 outpatients, indicating a substantial potential market for Catheter Precision's products [2] Market Expansion - The purchase order from Dubrava Hospital reflects the growing trust and enthusiasm among leading clinicians in Europe for Catheter Precision's technologies, suggesting potential for continued growth in the region [3]

Company Overview - Catheter Precision, Inc. is a U.S.-based medical device company focused on developing advanced products for the cardiac electrophysiology market [2] - The company aims to improve the treatment of cardiac arrhythmias through innovative technology and collaboration with physicians [2] Upcoming Special Meeting - A special meeting of stockholders is scheduled for October 10, 2025, with a record date of September 10, 2025 [1] - The company seeks stockholder approval to amend its Certificate of Incorporation to increase the authorized shares of common stock and to appoint WithumSmith+Brown, PC as the independent auditor for fiscal year 2026 [1] Proxy Materials - Catheter Precision plans to file proxy materials with the U.S. Securities and Exchange Commission (SEC) related to the solicitation of proxies for the special meeting [5] - Stockholders can access the Preliminary and Definitive Proxy Statement and other related documents for free on the SEC's website or the company's website [5] Participants in Solicitation - The company, its directors, and certain executive officers may be considered "participants" in the proxy solicitation for the special meeting [6] - Information regarding these participants and their interests will be included in the Proxy Statement and related materials [6]